Lowest Price Guaranteed
Pages
345
Last Updated
May 2026
View Count
20264
1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Future Estimates
3.2.2. Currency Coverage and Foreign Exchange Rate
3.2.2.1. Major Currencies Affecting the Market
3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
3.2.2.3. Impact of Foreign Exchange Rate Volatility on The Market
3.2.2.4. Strategies for Mitigating Foreign Exchange Risk
3.2.3. Trade Policies
3.2.3.1. Impact of Trade Barriers on the Market
3.2.3.2. Strategies for Mitigating the Risks Associated with Trade Barriers
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. Introduction to Nuclear Medicines and Radiopharmaceuticals
5.3. Historical Evolution of Radiopharmaceuticals
5.4. Applications of Radiopharmaceuticals
5.4.1. Nuclear Imaging / Diagnosis
5.4.2. Therapeutic Use
5.5. Production of Radiopharmaceuticals
5.6. Regulatory Framework for Radiopharmaceuticals
5.7. Need for Outsourcing Radiopharmaceuticals Manufacturing
5.8. Selecting a CMO Partner for Radiopharmaceuticals Manufacturing
5.9. Current Scenario and Future Prospects Related to Radiopharmaceuticals
6. MARKET LANDSCAPE (INDUSTRY PLAYERS)
6.1. Chapter Overview
6.2. Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by Company Size and Location of Headquarters
6.2.5. Analysis by Type of Company
6.2.6. Analysis by Location of Manufacturing Facilities
6.2.7. Analysis by Application Area
6.2.8. Analysis by Type of Company and Application Area
6.2.9. Analysis by Type of Diagnostic Radiopharmaceuticals Manufactured
6.2.9.1. Analysis by Type of PET Radiopharmaceuticals Manufactured
6.2.9.2. Analysis by Type of SPECT Radiopharmaceuticals Manufactured
6.2.10. Analysis by Type of Therapeutic Radiopharmaceuticals Manufactured
6.2.10.1. Analysis by Type of Beta Emitters Manufactured
6.2.10.2. Analysis by Type of Alpha Emitters Manufactured
6.2.11. Analysis by Type of Service Offered
6.2.12. Analysis by Type of Company and Type of Service Offered
6.2.13. Analysis by Scale of Operation
6.2.14. Analysis by Therapeutic Area
7. MARKET LANDSCAPE (NON-INDUSTRY PLAYERS)
7.1. Chapter Overview
7.2. Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Overall Market Landscape
7.2.1. Analysis by Location of Headquarters
7.2.2. Analysis by Type of Organization
7.2.3. Analysis by Application Area
7.2.4. Analysis by Type of Organization and Application Area
7.2.5. Analysis by Type of Diagnostic Radiopharmaceuticals Manufactured
7.2.5.1. Analysis by Type of PET Radiopharmaceuticals Manufactured
7.2.5.2. Analysis by Type of SPECT Radiopharmaceuticals Manufactured
7.2.6. Analysis by Type of Therapeutic Radiopharmaceuticals Manufactured
7.2.6.1. Analysis by Type of Beta Emitters Manufactured
7.2.7. Analysis by Purpose of Manufacturing
7.2.8. Analysis by Type of Organization and Purpose of Manufacturing
7.2.9. Analysis by Therapeutic Area
8. COMPANY COMPETITIVENSS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions / Key Parameters
8.3. Methodology
8.4. Nuclear Medicine and Radiopharmaceutical Manufacturers: Company Competitiveness Analysis
8.4.1. Nuclear Medicine and Radiopharmaceuticals Manufacturers based in North America (Peer Group I)
8.4.2. Nuclear Medicine and Radiopharmaceuticals Manufacturers based in Europe (Peer Group II)
8.4.3. Nuclear Medicine and Radiopharmaceuticals Manufacturers based in Asia-Pacific, Middle East and North Africa, and Rest of the World (Peer Group III)
9. COMPANY PROFILES
9.1. Chapter Overview
9.2. Advanced Accelerator Applications
9.2.1. Company Overview
9.2.2. Financial Information
9.2.3. List of Radiopharmaceuticals and Location of Manufacturing Facilities
9.2.4. Service Portfolio
9.2.5. Recent Developments and Future Outlook
9.3. Cardinal Health
9.3.1. Company Overview
9.3.2. Financial Information
9.3.3. List of Radiopharmaceuticals and Location of Manufacturing Facilities
9.3.4. Service Portfolio
9.3.5. Recent Developments and Future Outlook
9.4. DuChemBio
9.4.1. Company Overview
9.4.2. List of Radiopharmaceuticals and Location of Manufacturing Facilities
9.4.3. Service Portfolio
9.4.4. Recent Developments and Future Outlook
9.5. Eckert & Ziegler
9.5.1. Company Overview
9.5.2. Financial Information
9.5.3. List of Radiopharmaceuticals and Location of Manufacturing Facilities
9.5.4. Service Portfolio
9.5.5. Recent Developments and Future Outlook
9.6. ITM Isotope Technologies Munich
9.6.1. Company Overview
9.6.2. List of Radiopharmaceuticals and Location of Manufacturing Facilities
9.6.3. Service Portfolio
9.6.4. Recent Developments and Future Outlook
9.7. Nihon Medi-Physics
9.7.1. Company Overview
9.7.2. List of Radiopharmaceuticals and Location of Manufacturing Facilities
9.7.3. Service Portfolio
9.7.4. Recent Developments and Future Outlook
9.8. PharmaLogic
9.8.1. Company Overview
9.8.2. List of Radiopharmaceuticals and Location of Manufacturing Facilities
9.8.3. Service Portfolio
9.8.4. Recent Developments and Future Outlook
9.9. Other Leading Players
9.9.1. Applied Molecular Therapies
9.9.1.1. Company Overview
9.9.1.2. List of Radiopharmaceuticals and Location of Manufacturing Facilities
9.9.1.3. Service Portfolio
9.9.2. Evergreen Theragnostics
9.9.2.1. Company Overview
9.9.2.2. List of Radiopharmaceuticals and Location of Manufacturing Facilities
9.9.2.3. Service Portfolio
9.9.3. Isotopia Molecular Imaging
9.9.3.1. Company Overview
9.9.3.2. List of Radiopharmaceuticals and Location of Manufacturing Facilities
9.9.3.3. Service Portfolio
9.9.4. Nucleus RadioPharma
9.9.4.1. Company Overview
9.9.4.2. List of Radiopharmaceuticals and Location of Manufacturing Facilities
9.9.4.3. Service Portfolio
9.9.5. Pentixapharm
9.9.5.1. Company Overview
9.9.5.2. List of Radiopharmaceuticals and Location of Manufacturing Facilities
9.9.6. RadioMedix
9.9.6.1. Company Overview
9.9.6.2. List of Radiopharmaceuticals and Location of Manufacturing Facilities
9.9.6.3. Service Portfolio
9.9.7. SOFIE
9.9.7.1. Company Overview
9.9.7.2. List of Radiopharmaceuticals and Location of Manufacturing Facilities
9.9.7.3. Service Portfolio
9.9.8. Telix Pharmaceuticals
9.9.8.1. Company Overview
9.9.8.2. List of Radiopharmaceuticals and Location of Manufacturing Facilities
9.9.8.3. Service Portfolio
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Nuclear Medicine and Radiopharmaceutical Manufacturing: Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Year and Type of Partnership
10.3.4. Analysis by Application Area
10.3.5. Analysis by Type of Radioisotope Involved
10.3.6. Analysis by Type of Partner
10.3.7. Most Active Players: Analysis by Number of Partnerships
10.3.8. Analysis by Geography
10.3.8.1. Local and International Deals
10.3.8.2. Intercontinental and Intracontinental Deals
11. PRODUCTION AND SUPPLY CHAIN OF MOLYBDENUM-99 (TECHNETIUM-99M)
11.1. Chapter Overview
11.2. Production and Use of Mo-99
11.3. Supply Chain of Mo-99
11.3.1. Target Suppliers
11.3.2. Irradiation of Mo-99
11.3.3. Mo-99 Suppliers
11.3.4. Technetium Generator Suppliers
11.3.5. Tc-99 Suppliers
11.4. Supply Interruptions
11.5. Future Prospects
12. GAP ASSESSMENT FRAMEWORK
12.1. Chapter Overview
12.2. Nuclear Medicine and Radiopharmaceutical Manufacturing Market: Gap Assessment Framework
12.2.1. Methodology
12.2.2. Key Parameters
12.2.2.1. Gap Assessment: Economic Infrastructure
12.2.2.2. Gap Assessment: Compliance Assurance
12.2.2.3. Gap Assessment: Streamlined Production
12.2.3. Strategic Roadmap to Address Market Gap
12.3. Regional Gap Assessment
12.3.1. Methodology
12.3.2. Regional Gap Assessment of Manufacturing Facilities in America
12.3.3. Regional Gap Assessment of Manufacturing Facilities in Europe
12.3.4. Regional Gap Assessment of Manufacturing Facilities in Asia-Pacific and Middle East
12.4. Concluding Remarks
13. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
13.1. Chapter Overview
13.2. Market Drivers
13.3. Market Restraints
13.4. Market Opportunities
13.5. Market Challenges
13.6. Conclusion
14. GLOBAL NUCLEAR MEDICINE AND RADIOPHARMACEUTICAL MANUFACTURING MARKET
14.1. Chapter Overview
14.2. Assumptions and Methodology
14.3. Global Nuclear Medicine and Radiopharmaceutical Manufacturing Market, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
14.3.1. Scenario Analysis
14.3.1.1. Conservative Scenario
14.3.1.2. Optimistic Scenario
14.4. Key Market Segmentations
15. NUCLEAR MEDICINE AND RADIOPHARMACEUTICAL MANUFACTURING MARKET: DISTRIBUTION BY APPLICATION AREA
15.1. Chapter Overview
15.2. Assumptions and Methodology
15.3. Nuclear Medicine and Radiopharmaceutical Manufacturing Market: Distribution by Application Area, 2024 and 2035
15.3.1. Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Diagnostic Radiopharmaceuticals: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
15.3.2. Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Therapeutic Radiopharmaceuticals: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
15.4. Data Triangulation and Validation
16. NUCLEAR MEDICINE AND RADIOPHARMACEUTIAL MANUFACTURING MARKET: DISTRIBUTION BY TYPE OF DIAGNOSTIC RADIOPHARMACEUTICAL
16.1. Chapter Overview
16.2. Assumptions and Methodology
16.3. Nuclear Medicine and Radiopharmaceutical Manufacturing Market: Distribution by Type of Diagnostic Radiopharmaceutical, 2024 and 2035
16.3.1. Nuclear Medicine and Radiopharmaceutical Manufacturing Market for PET Radiopharmaceuticals: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
16.3.2. Nuclear Medicine and Radiopharmaceutical Manufacturing Market for SPECT Radiopharmaceuticals: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
16.4. Data Triangulation and Validation
17. NUCLEAR MEDICINE AND RADIOPHARMACEUTICAL MANUFACTURING MARKET: DISTRIBUTION BY TYPE OF THERAPEUTIC RADIOPHARMACEUTICAL
17.1. Chapter Overview
17.2. Assumptions and Methodology
17.3. Nuclear Medicine and Radiopharmaceutical Manufacturing Market: Distribution by Type of Therapeutic Radiopharmaceutical, 2024 and 2035
17.3.1. Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Alpha Emitters: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
17.3.2. Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Beta Emitters: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
17.3.3. Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Other Therapeutic Radiopharmaceuticals: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
17.4. Data Triangulation and Validation
18. NUCLEAR MEDICINE AND RADIOPHARMACEUTICAL MANUFACTURING MARKET: DISTRIBUTION BY TYPE OF RADIOISOTOPE
18.1. Chapter Overview
18.2. Assumptions and Methodology
18.3. Nuclear Medicine and Radiopharmaceutical Manufacturing Market: Distribution by Type of Radioisotope, 2024 and 2035
18.3.1. Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Technetium-99m Radioisotopes: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
18.3.2. Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Fluorine-18 Radioisotopes: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
18.3.3. Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Leutetium-177 Radioisotopes: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
18.3.4. Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Gallium-68 Radioisotopes: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
18.3.5. Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Actinium-225 Radioisotopes: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
18.3.6. Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Other Radioisotopes: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
18.4. Data Triangulation and Validation
19. NUCLEAR MEDICINE AND RADIOPHARMACEUTICAL MANUFACTURING MARKET: DISTRIBUTION BY PURPOSE OF MANUFACTURING
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Nuclear Medicine and Radiopharmaceutical Manufacturing Market: Distribution by Purpose of Manufacturing, 2024 and 2035
19.3.1. Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Contract Manufacturing Market: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
19.3.2. Nuclear Medicine and Radiopharmaceutical Manufacturing Market for In-House Manufacturing Market: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
19.4. Data Triangulation and Validation
20. NUCLEAR MEDICINE AND RADIOPHARMACEUTICAL MANUFACTURING MARKET: DISTRIBUTION BY SOURCE OF MANUFACTURING
20.1. Chapter Overview
20.2. Assumptions and Methodology
20.3. Nuclear Medicine and Radiopharmaceutical Manufacturing Market: Distribution by Source of Manufacturing, 2024 and 2035
20.3.1. Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Nuclear Reactors: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
20.3.2. Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Cyclotrons: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
20.4. Data Triangulation and Validation
21. NUCLEAR MEDICINE AND RADIOPHARMACEUTICAL MANUFACTURING MARKET: DISTRIBUTION BY SCALE OF OPERATION
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Nuclear Medicine and Radiopharmaceutical Manufacturing Market: Distribution by Scale of Operation, 2024 and 2035
21.3.1. Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Preclinical Scale: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
21.3.2. Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Clinical Scale: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
21.3.3. Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Commercial Scale: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
21.4. Data Triangulation and Validation
22. NUCLEAR MEDICINE AND RADIOPHARMACEUTICAL MANUFACTURING MARKET: DISTRIBUTION BY THERAPEUTIC AREA
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Nuclear Medicine and Radiopharmaceutical Manufacturing Market: Distribution by Therapeutic Area, 2024 and 2035
22.3.1. Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Cardiovascular Disorders: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
22.3.2. Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Neurological Disorders: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
22.3.3. Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Oncological Disorders: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
22.3.4. Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Other Disorders: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
22.4. Data Triangulation
23. NUCLEAR MEDICINE AND RADIOPHARMACEUTICAL MANUFACTURING MARKET: DISTRIBUTION BY KEY GEOGRAPHICAL REGIONS
23.1. Chapter Overview
23.2. Assumptions and Methodology
23.3. Nuclear Medicine and Radiopharmaceutical Manufacturing Market: Distribution by Key Geographical Regions, 2024 and 2035
23.3.1. Nuclear Medicine and Radiopharmaceutical Manufacturing Market in North America: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
23.3.2. Nuclear Medicine and Radiopharmaceutical Manufacturing Market in Europe: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
23.3.3. Nuclear Medicine and Radiopharmaceutical Manufacturing Market in Asia-Pacific: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
23.3.4. Nuclear Medicine and Radiopharmaceutical Manufacturing Market in Rest of the World: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035)
23.4. Data Triangulation and Validation
24. CONCLUSION
25 EXECUTIVE INSIGHTS
26 APPENDIX 1: TABULATED DATA
27 APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Forecast Methodology
Figure 2.3 Research Methodology: Robust Quality Control
Figure 2.4 Research Methodology: Key Market Segmentations
Figure 3.1 Lessons Learnt from Past Recessions
Figure 4.1 Executive Summary: Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Market Landscape
Figure 4.2 Executive Summary: Nuclear Medicine and Radiopharmaceutical Manufacturers (Non-Industry Players): Market Landscape
Figure 4.3 Executive Summary: Partnerships and Collaborations
Figure 4.4 Executive Summary: Nuclear Medicine and Radiopharmaceutical Manufacturing: Market Forecast and Opportunity Analysis (I/II)
Figure 4.5 Executive Summary: Nuclear Medicine and Radiopharmaceutical Manufacturing: Market Forecast and Opportunity Analysis (II/II)
Figure 5.1 Structure of a Radiopharmaceutical
Figure 5.2 Production of Radiopharmaceuticals: Radionuclide Generator
Figure 5.3 Production of Radiopharmaceuticals: Particle Accelerator (Cyclotron)
Figure 5.4 Production of Radiopharmaceuticals: Nuclear Reactor
Figure 5.5 Geographical Distribution of Regulatory Bodies Governing the Production of Radiopharmaceuticals
Figure 5.6 Selecting a CMO Partner for Radiopharmaceuticals Production: Parameters to Consider
Figure 6.1 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Year of Establishment
Figure 6.2 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Company Size
Figure 6.3 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Location of Headquarters
Figure 6.4 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Company Size and Location of Headquarters
Figure 6.5 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of Company
Figure 6.6 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Location of Manufacturing Facilities
Figure 6.7 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Application Area
Figure 6.8 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of Company and Application Area
Figure 6.9 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of Diagnostic Radiopharmaceuticals Manufactured
Figure 6.10 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of PET Radiopharmaceuticals Manufactured
Figure 6.11 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of SPECT Radiopharmaceuticals Manufactured
Figure 6.12 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of Therapeutic Radiopharmaceuticals Manufactured
Figure 6.13 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of Beta Emitters Manufactured
Figure 6.14 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of Alpha Emitters Manufactured
Figure 6.15 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of Service Offered
Figure 6.16 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of Company and Type of Service Offered
Figure 6.17 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Scale of Operation
Figure 6.18 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Therapeutic Area
Figure 7.1 Nuclear Medicine and Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Location of Headquarters
Figure 7.2 Nuclear Medicine and Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Type of Organization
Figure 7.3 Nuclear Medicine and Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Application area
Figure 7.4 Nuclear Medicine and Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Type of Organization and Application area
Figure 7.5 Nuclear Medicine and Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Type of Diagnostic Radiopharmaceuticals Manufactured
Figure 7.6 Nuclear Medicine and Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Type of PET Radiopharmaceuticals Manufactured
Figure 7.7 Nuclear Medicine and Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Type of SPECT Radiopharmaceuticals Manufactured
Figure 7.8 Nuclear Medicine and Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Type of Therapeutic Radiopharmaceuticals Manufactured
Figure 7.9 Nuclear Medicine and Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Type of Beta Emitters Manufactured
Figure 7.10 Nuclear Medicine and Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Purpose of Manufacturing
Figure 7.11 Nuclear Medicine and Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Type of Organization and Purpose of Manufacturing
Figure 7.12 Nuclear Medicine and Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Therapeutic Area
Figure 8.1 Company Competitiveness Analysis: Players based in North America (Peer Group I)
Figure 8.2 Company Competitiveness Analysis: Players based in Europe (Peer Group II)
Figure 8.3 Company Competitiveness Analysis: Players based in Asia-Pacific, Middle East and North Africa and Rest of the World (Peer Group III)
Figure 9.1 Novartis: Annual Revenues, FY 2019 – FY 2023 (USD Billion)
Figure 9.2 Advanced Accelerator Applications: Service Portfolio
Figure 9.3 Cardinal Health: Annual Revenues, FY 2019 – Q1 FY 2024 (USD Billion)
Figure 9.4 Cardinal Health: Service Portfolio
Figure 9.5 DuChemBio: Service Portfolio
Figure 9.6 Eckert & Ziegler: Annual Revenues, FY 2019 – Q3 FY 2023 (EUR Million)
Figure 9.7 Eckert & Ziegler: Service Portfolio
Figure 9.8 ITM Isotope Technologies Munich: Service Portfolio
Figure 9.9 Nihon Medi-Physics: Service Portfolio
Figure 9.10 PharmaLogic: Service Portfolio
Figure 9.11 Applied Molecular Therapies: Service Portfolio
Figure 9.12 Evergreen Theragnostics: Service Portfolio
Figure 9.13 Isotopia Molecular Imaging: Service Portfolio
Figure 9.14 Nucleus RadioPharma: Service Portfolio
Figure 9.15 RadioMedix: Service Portfolio
Figure 9.16 SOFIE: Service Portfolio
Figure 9.17 Telix Pharmaceuticals: Service Portfolio
Figure 10.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2019-2023
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2019-2023
Figure 10.4 Partnerships and Collaborations: Distribution by Application Area
Figure 10.5 Partnerships and Collaborations: Distribution by Type of Radioisotope Involved
Figure 10.6 Partnerships and Collaborations: Distribution by Type of Partner
Figure 10.7 Most Active Players: Distribution by Number of Partnerships
Figure 10.8 Partnerships and Collaborations: Distribution by Local and International Agreements
Figure 10.9 Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Deals
Figure 11.1 Supply Chain of Mo-99 (Tc-99m)
Figure 11.2 Geographical Location of Major Nuclear Reactors
Figure 12.1 Strategic Roadmap: Short, Mid and Long-Term Initiatives
Figure 12.2 Regional Gap Assessment of Manufacturing Facilities in America (in terms of Application Areas)
Figure 12.3 Regional Gap Assessment of Manufacturing Facilities in Europe (in terms of Application Areas)
Figure 12.4 Regional Gap Assessment of Manufacturing Facilities in Aisa-Pacific and Middle East (in terms of Application Areas)
Figure 13.1 Market Impact Analysis: Drivers
Figure 13.2 Market Impact Analysis: Restraints
Figure 13.3 Market Impact Analysis: Opportunities
Figure 13.4 Market Impact Analysis: Challenges
Figure 14.1 Global Nuclear Medicine and Radiopharmaceutical Manufacturing Market, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035): Base Scenario (USD Billion)
Figure 14.2 Global Nuclear Medicine and Radiopharmaceutical Manufacturing Market, Forecasted Estimates (2024-2035): Conservative Scenario (USD Billion)
Figure 14.3 Global Nuclear Medicine and Radiopharmaceutical Manufacturing Market, Forecasted Estimates (2024-2035): Optimistic Scenario (USD Billion)
Figure 15.1 Nuclear Medicine and Radiopharmaceutical Manufacturing Market: Distribution by Application Area, 2024 and 2035
Figure 15.2 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Diagnostic Radiopharmaceuticals: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 15.3 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Therapeutic Radiopharmaceuticals: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 16.1 Nuclear Medicine and Radiopharmaceutical Manufacturing Market: Distribution by Type of Diagnostic Radiopharmaceutical, 2024 and 2035
Figure 16.2 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for PET Radiopharmaceuticals: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 16.3 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for SPECT Radiopharmaceuticals: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 17.1 Nuclear Medicine and Radiopharmaceutical Manufacturing Market: Distribution by Type of Therapeutic Radiopharmaceutical, 2024 and 2035
Figure 17.2 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Alpha Emitters: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 17.3 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Beta Emitters: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 17.4 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Other Therapeutic Radiopharmaceuticals: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.1 Nuclear Medicine and Radiopharmaceutical Manufacturing Market: Distribution by Type of Radioisotope, 2024 and 2035
Figure 18.2 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Technetium-99m Radioisotopes: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.3 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Fluorine-18 Radioisotopes: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.4 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Leutetium-177 Radioisotopes: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.5 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Gallium-68 Radioisotopes: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.6 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Actinium-225 Radioisotopes: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.7 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Other Radioisotopes: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 19.1 Nuclear Medicine and Radiopharmaceutical Manufacturing Market: Distribution by Purpose of Manufacturing, 2024 and 2035
Figure 19.2 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Contract Manufacturing: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 19.3 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for In-House Manufacturing: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 20.1 Nuclear Medicine and Radiopharmaceutical Manufacturing Market: Distribution by Source of Manufacturing, 2024 and 2035
Figure 20.2 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Nuclear Reactors: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 20.3 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Cyclotrons: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 21.1 Nuclear Medicine and Radiopharmaceutical Manufacturing Market: Distribution by Scale of Operation, 2024 and 2035
Figure 21.2 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Preclinical Scale: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 21.3 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Clinical Scale: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 21.4 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Commercial Scale: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.1 Nuclear Medicine and Radiopharmaceutical Manufacturing Market: Distribution by Therapeutic Area, 2024 and 2035 (USD Billion)
Figure 22.2 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Cardiovascular Disorders: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.3 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Neurological Disorders: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.4 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Oncological Disorders: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 22.5 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Other Disorders: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 23.1 Nuclear Medicine and Radiopharmaceutical Manufacturing Market: Distribution by Key Geographical Regions, 2024 and 2035
Figure 23.2 Nuclear Medicine and Radiopharmaceutical Manufacturing Market in North America: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 23.3 Nuclear Medicine and Radiopharmaceutical Manufacturing Market in Europe: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 23.4 Nuclear Medicine and Radiopharmaceutical Manufacturing Market in Asia- Pacific: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 23.5 Nuclear Medicine and Radiopharmaceutical Manufacturing Market in Rest of the World: Historical Trends (2019-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 24.1 Conclusion: Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players) Market Landscape
Figure 24.2 Conclusion: Nuclear Medicine and Radiopharmaceutical Manufacturers (Non-Industry Players) Market Landscape
Figure 24.3 Conclusion: Partnerships and Collaborations
Figure 24.4 Conclusion: Market Forecast and Opportunity Analysis (I/III)
Figure 24.5 Conclusion: Market Forecast and Opportunity Analysis (II/III)
Figure 24.6 Conclusion: Market Forecast and Opportunity Analysis (III/III)
Table 5.1 List of Commonly Used SPECT Radionuclides
Table 5.2 List of Commonly Used PET Radionuclides
Table 5.3 List of Commonly Used Radionuclides for Therapeutic Applications
Table 5.4 List of Radionuclides Produced Using Generator, Particle Accelerator (Cyclotron) and Reactor Produced
Table 5.5 List of the USFDA Approved Radiopharmaceuticals
Table 6.1 Nuclear Medicine and Radiopharmaceuticals Manufacturers: List of Industry Players
Table 6.2 Nuclear Medicine and Radiopharmaceuticals Manufacturers: Information on Location of Manufacturing Facilities and Application area
Table 6.3 Nuclear Medicine and Radiopharmaceutical Manufacturers: Information on Type of Diagnostic Radiopharmaceuticals Manufactured
Table 6.4 Nuclear Medicine and Radiopharmaceutical Manufacturers: Information on Type of Therapeutic Radiopharmaceuticals Manufactured
Table 6.5 Nuclear Medicine and Radiopharmaceutical Manufacturers: Information on Type of Service Offered
Table 6.6 Nuclear Medicine and Radiopharmaceutical Manufacturers: Information on Scale of Operation
Table 6.7 Nuclear Medicine and Radiopharmaceutical Manufacturers: Information on Therapeutic Area
Table 7.1 Nuclear Medicine and Radiopharmaceuticals Manufacturers: List of Non-Industry Players
Table 7.2 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Information on Application area and Type of Diagnostic Radiopharmaceuticals Manufactured
Table 7.3 Nuclear Medicine and Radiopharmaceutical Manufacturers (Non-Industry Players): Information on Type of PET Radiopharmaceuticals Manufactured
Table 7.4 Nuclear Medicine and Radiopharmaceutical Manufacturers (Non-Industry Players): Information on Type of SPECT Radiopharmaceuticals Manufactured
Table 7.5 Nuclear Medicine and Radiopharmaceutical Manufacturers (Non-Industry Players): Information on Type of Therapeutic Radiopharmaceuticals Manufactured
Table 7.6 Nuclear Medicine and Radiopharmaceutical Manufacturers (Non-Industry Players): Information on Type of Beta Emitters Radiopharmaceuticals Manufactured
Table 7.7 Nuclear Medicine and Radiopharmaceutical Manufacturers (Non-Industry Players): Information on Purpose of Manufacturing
Table 7.8 Nuclear Medicine and Radiopharmaceutical Manufacturers (Non-Industry Players): Information on Therapeutic Area
Table 9.1 Nuclear Medicine and Radiopharmaceutical Manufacturers: List of Companies Profiled
Table 9.2 Advanced Accelerator Applications: Company Overview
Table 9.3 Advanced Accelerator Applications: List of Radiopharmaceuticals and Location of Manufacturing Facilities
Table 9.4 Advanced Accelerator Applications: Recent Developments and Future Outlook
Table 9.5 Cardinal Health: Company Overview
Table 9.6 Cardinal Health: List of Radiopharmaceuticals and Location of Manufacturing Facilities
Table 9.7 Cardinal Health: Recent Developments and Future Outlook
Table 9.8 DuChemBio: Company Overview
Table 9.9 DuChemBio: List of Radiopharmaceuticals and Location of Manufacturing Facilities
Table 9.10 Eckert & Ziegler: Company Overview
Table 9.11 Eckert & Ziegler: List of Radiopharmaceuticals and Location of Manufacturing Facilities
Table 9.12 Eckert & Ziegler: Recent Developments and Future Outlook
Table 9.13 ITM Isotope Technologies Munich: Company Overview
Table 9.14 ITM Isotope Technologies Munich: List of Radiopharmaceuticals and Location of Manufacturing Facilities
Table 9.15 ITM Isotope Technologies Munich: Recent Developments and Future Outlook
Table 9.16 Nihon Medi-Physics: Company Overview
Table 9.17 Nihon Medi-Physics: List of Radiopharmaceuticals and Location of Manufacturing Facilities
Table 9.18 Nihon Medi-Physics: Recent Developments and Future Outlook
Table 9.19 PharmaLogic: Company Overview
Table 9.20 PharmaLogic: List of Radiopharmaceuticals and Location of Manufacturing Facilities
Table 9.21 PharmaLogic: Recent Developments and Future Outlook
Table 9.22 Applied Molecular Therapies: Company Overview
Table 9.23 Applied Molecular Therapies: List of Radiopharmaceuticals and Location of Manufacturing Facilities
Table 9.24 Evergreen Theragnostics: Company Overview
Table 9.25 Evergreen Theragnostics: List of Radiopharmaceuticals and Location of Manufacturing Facilities
Table 9.26 Isotopia Molecular Imaging: Company Overview
Table 9.27 Isotopia Molecular Imaging: List of Radiopharmaceuticals and Location of Manufacturing Facilities
Table 9.28 Nucleus RadioPharma: Company Overview
Table 9.29 Nucleus RadioPharma: Location of Manufacturing Facilities
Table 9.30 Pentixapharm: Company Overview
Table 9.31 Pentixapharm: List of Radiopharmaceuticals and Location of Manufacturing Facilities
Table 9.32 RadioMedix: Company Overview
Table 9.33 RadioMedix: List of Radiopharmaceuticals and Location of Manufacturing Facilities
Table 9.34 SOFIE: Company Overview
Table 9.35 SOFIE: List of Radiopharmaceuticals and Location of Manufacturing Facilities
Table 9.36 Telix Pharmaceuticals: Company Overview
Table 9.37 Telix Pharmaceuticals: List of Radiopharmaceuticals and Location of Manufacturing Facilities
Table 10.1 Nuclear Medicine and Radiopharmaceutical Manufacturing: List of Partnerships and Collaborations, 2019-2023
Table 11.1 List of Nuclear Reactors for Irradiation of Uranium Targets
Table 11.2 List of Global Mo-99 Suppliers
Table 11.3 List of Planned / Unplanned Mo-99 Reactor or Supplier Complete Shutdown (2002-2023)
Table 12.1 Gap Assessment: Economic Infrastructure
Table 12.2 Gap Assessment: Compliance Assurance
Table 12.3 Gap Assessment: Streamlined Production
Table 26.1 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Year of Establishment
Table 26.2 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Company Size
Table 26.3 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Location of Headquarters
Table 26.4 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Company Size and Location of Headquarters
Table 26.5 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of Company
Table 26.6 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Location of Manufacturing Facilities
Table 26.7 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Application area
Table 26.8 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of Company and Application Area
Table 26.9 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of Diagnostic Radiopharmaceuticals Manufactured
Table 26.10 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of PET Radiopharmaceuticals Manufactured
Table 26.11 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of SPECT Radiopharmaceuticals Manufactured
Table 26.12 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of Therapeutic Radiopharmaceuticals Manufactured
Table 26.13 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of Beta Emitters Manufactured
Table 26.14 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of Alpha Emitters Manufactured
Table 26.15 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of Service Offered
Table 26.16 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of Company and Type of Service Offered
Table 26.17 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Scale of Operation
Table 26.18 Nuclear Medicine and Radiopharmaceutical Manufacturers (Industry Players): Distribution by Therapeutic Area
Table 26.19 Nuclear Medicine and Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Location of Headquarters
Table 26.20 Nuclear Medicine and Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Type of Organization
Table 26.21 Nuclear Medicine and Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Application area
Table 26.22 Nuclear Medicine and Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Type of Organization and Application area
Table 26.23 Nuclear Medicine and Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Type of Diagnostic Radiopharmaceuticals Manufactured
Table 26.24 Nuclear Medicine and Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Type of PET Radiopharmaceuticals Manufactured
Table 26.25 Nuclear Medicine and Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Type of SPECT Radiopharmaceuticals Manufactured
Table 26.26 Nuclear Medicine and Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Type of Therapeutic Radiopharmaceuticals Manufactured
Table 26.27 Nuclear Medicine and Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Type of Beta Emitters Manufactured
Table 26.28 Nuclear Medicine and Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Purpose of Manufacturing
Table 26.29 Nuclear Medicine and Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Type of Organization and Purpose of Manufacturing
Table 26.30 Nuclear Medicine and Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Therapeutic Area
Table 26.31 Partnerships and Collaborations: Year of Partnership, 2019-2023
Table 26.32 Partnerships and Collaborations: Distribution by Type of Partnership
Table 26.33 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 26.34 Partnerships and Collaborations: Distribution by Type of Partner
Table 26.35 Partnerships and Collaborations: Distribution by Application area
Table 26.36 Partnerships and Collaborations: Distribution by Type of Radioisotope Involved
Table 26.37 Most Active Players: Distribution by Number of Partnerships
Table 26.38 Partnerships and Collaborations: Distribution by Local and International Agreements
Table 26.39 Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreement
Table 26.40 Global Nuclear Medicine and Radiopharmaceutical Manufacturing Market, Historical Trends (2019-2023) and Forecasted Estimates (2024-2035): Base Scenario (USD Billion)
Table 26.41 Global Nuclear Medicine and Radiopharmaceutical Manufacturing Market, Forecasted Estimates (2024-2035): Conservative Scenario (USD Billion)
Table 26.42 Global Nuclear Medicine and Radiopharmaceutical Manufacturing Market, Forecasted Estimates (2024-2035): Optimistic Scenario (USD Billion)
Table 26.43 Nuclear Medicine and Radiopharmaceutical Manufacturing Market: Distribution by Application Area, 2024 and 2035
Table 26.44 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Diagnostic Radiopharmaceuticals, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.45 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Therapeutic Radiopharmaceuticals, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.46 Nuclear Medicine and Radiopharmaceutical Manufacturing Market: Distribution by Type of Diagnostic Radiopharmaceutical, 2024 and 2035
Table 26.47 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for PET Radiopharmaceuticals, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.48 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for SPECT Radiopharmaceuticals, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.49 Nuclear Medicine and Radiopharmaceutical Manufacturing Market: Distribution by Type of Therapeutic Radiopharmaceutical, 2024 and 2035
Table 26.50 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Alpha Emitters, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.51 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Beta Emitters, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.52 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Other Therapeutic Radiopharmaceuticals, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.53 Nuclear Medicine and Radiopharmaceutical Manufacturing Market: Distribution by Type of Radioisotope, 2024 and 2035
Table 26.54 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Technetium-99m Radioisotopes, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.55 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Fluorine-18 Radioisotopes, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.56 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Leutetium-177 Radioisotopes, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.57 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Gallium-68 Radioisotopes, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.58 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Actinium-225 Radioisotopes, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.59 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Other Radioisotopes, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.60 Nuclear Medicine and Radiopharmaceutical Manufacturing Market: Distribution by Purpose of Manufacturing, 2024 and 2035
Table 26.61 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Contract Manufacturing, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.62 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for In-House Manufacturing, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.63 Nuclear Medicine and Radiopharmaceutical Manufacturing Market: Distribution by Source of Manufacturing, 2024 and 2035
Table 26.64 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Nuclear Reactors, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.65 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Cyclotrons, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.66 Nuclear Medicine and Radiopharmaceutical Manufacturing Market: Distribution by Scale of Operation, 2024 and 2035
Table 26.67 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Preclinical Scale, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.68 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Clinical Scale, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.69 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Commercial Scale, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.70 Nuclear Medicine and Radiopharmaceutical Manufacturing Market: Distribution by Therapeutic Area, 2024 and 2035
Table 26.71 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Cardiovascular Disorders, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.72 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Neurological Disorders, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.73 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Oncological Disorders, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.74 Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Other Disorders, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.75 Nuclear Medicine and Radiopharmaceutical Manufacturing Market: Distribution by Key Geographical Regions, 2024 and 2035
Table 26.76 Nuclear Medicine and Radiopharmaceutical Manufacturing Market in North America, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.77 Nuclear Medicine and Radiopharmaceutical Manufacturing Market in Europe, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.78 Nuclear Medicine and Radiopharmaceutical Manufacturing Market in Asia-Pacific, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.79 Nuclear Medicine and Radiopharmaceutical Manufacturing Market in Rest of the World, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Please reach out to our team for the details.